Feature Channels

Pharmaceuticals

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Keywords:

Penn Researchers Find Naltrexone May Be Effective in Diminishing Impulse Control Disorders in Parkinson's Disease Patients

Parkinson's disease (PD) patients may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending. A team of investigators from the Perelman School of Medicine at the University of Pennsylvania and the Parkinson's Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical Center conducted a pilot study and found that the opioid antagonist naltrexone may be an effective treatment for diminishing ICD symptoms in PD patients. The results were published in the journal Neurology.

View | Comment

Medicine

Channels:

Keywords:

Parenting Skills Improve in ADHD Parents with Medication

WaxmonskyJamesWhitecoat.JPG

Parenting skills of adults with ADHD improve when their ADHD is treated with medication, according to Penn State College of Medicine researchers. At least 25 percent of clinic-referred children with attention deficit/hyperactivity disorder have a parent with ADHD.

View | Comment

Medicine

Science

Channels:

Keywords:

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 13-Aug-2014 5:00 AM EDT

Medicine

Science

Channels:

Keywords:

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 10-Aug-2014 5:00 AM EDT

Science

Channels:

Keywords:

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 10-Aug-2014 5:00 AM EDT

Science

Channels:

Keywords:

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 11-Aug-2014 5:00 AM EDT

Medicine

Channels:

Keywords:

Zerenex™ (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology

Keryx Biopharmaceuticals, Inc. announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. The PERFECTED study (PhosphatE binding and iRon delivery with FErric CiTrate in EsrD) was published online today in the Journal of the American Society of Nephrology (JASN).

View | Comment

Medicine

Channels:

Keywords:

Drug Approved to Treat Rare Disorder Associated with Anesthesia

henry-rosenberg.jpg

Eagle Pharmaceuticals, Inc. today announced the U. S. Food and Drug Administration (FDA) has approved Ryanodex® (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia (MH), along with the appropriate supportive measures. MH is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. FDA had designated Ryanodex as an Orphan Drug in August 2013. Eagle has been informed by the FDA that it will learn over the next four to six weeks if it has been granted the seven year Orphan Drug market exclusivity.

View | Comment

Medicine

Channels:

Keywords:

UNC Researchers Find Unsuspected Characteristics of New CF Drugs

correction_potentiation.jpg

In lab experiments using tissue samples cultured from cystic fibrosis patients, scientists at the UNC School of Medicine and the UNC Marsico Lung Institute have shown that a new CF drug counteracts the intended beneficial molecular effect of another CF drug.

View | Comment

Medicine

Channels:

Keywords:

COLA Leadership Summit Concludes with a Path Forward

COLA, the largest private accreditor of medical laboratories serving more than 8,000 across the U.S., successfully concluded its 2014 Leadership Summit in April. More than 30 thought leaders in health care, including physicians, regulators, public health experts, medical laboratory scientists, manufacturers, nurse practitioners and more gathered in San Francisco to discuss the future of laboratory medicine in the context of the Affordable Care Act (ACA). The group explored the implications of the dynamics of ACA and changing payment policies on quality and learning in laboratory medicine.

View | Comment